Stock code 7776, Selseed, increased by 80 points to 434. Stock code 4882, Perseus, also rose by 80 points to 519. Both stocks have hit their daily limit. After the end of transactions on 28th May, the company announced that Phase 1 trials of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody under development, in patients with true polycythemia (PV) had been completed. The test of the sixth and final patient was terminated by the patient's own intention, and the study ended after completing the mandated observations. The company states that there were no serious adverse events reported that raised safety concerns and that there are no changes in the outcome plan, such as the impact on performance this year or by the end of March 2025.